Abstract. The breaking of immune tolerance against self epidermal growth factor receptor (EGFR) should be a promising approach for the treatment of those receptorpositive tumors. We have previously shown that human EGFR as a xenoantigen induced a specific antitumor activity against EGFR-positive mouse tumors. Our further studies demonstrated that a recombinant form of extracellular domain of mouse EGFR provoked active cellular immunity responses against EGFR-positive human tumors. In this study, we investigated whether the recombinant murine EGFR expressed in the yeast Pichia pastoris would induce humoral immunity responses against EGFR-positive human tumors. To test this concept, polyclonal immunoglobulin (IgG), which was produced by vaccinating the rabbits with the recombinant mEGFR, was purified from the sera of the rabbits. We evaluated the antitumor activity of the polyclonal IgG in the nude mice bearing A431 tumors. Mice were i.v. treated with the purified IgG at 100 mg/kg 1 day before the mice were inoculated with the tumor cells and then twice per week for 4 weeks. Our results showed that the polyclonal IgG would efficiently inhibit the growth of the solid tumor in vivo. The antitumor effect of the polyclonal IgG may result from the increasing rate of apoptosis and induction of differentiation of the tumor cells in vivo. The present findings may provide insight into treatment of EGFRpositive tumors through induction of the humoral immunity responses based on xenogeneic homologous EGFR.
Introduction
EGFR belongs to the erbB receptor tyrosine kinase family consisting of four related transmembrane glycoprotein membrane receptors: EGFR/ErbB1/HER1, ErbB2/Neu/HER2, ErbB3/HER3 and ErbB4/HER4 (1) . Increased expression of EGFR can markedly influence the growth properties of cells and leads to tumor development in nude mice in an EGFdependent manner (2, 3) . In addition, autocrine and paracrine growth factor stimulation of the tumor is predominantly mediated by an EGFR-related pathway (4) , which can result in growth advantage of tumor cells. Moreover, in many human tumors, EGFR is often overexpressed and/or mutated with its constitutive activation leading to proliferation, reduced apoptosis, increased angiogenesis, increased motility, invasion and metastasis (5) .
The overexpression and aberrant function of EGFR and its ligands and co-receptors in a wide spectrum of epithelial cancers make it an ideal target for strategies to treat human tumors (1) . Accordingly, monoclonal antibodies (mAb) which are targeted the extracellular ligand-binding, domain or the intracellular tyrosine kinase signaling cascade of EGFR have shown efficacy as antitumor agents. Administration of antibodies, such as cetuximab, ABX-EGF and mAb 806 is capable of inhibiting tumor growth through both certain direct and indirect mechanisms (6) (7) (8) .
The breaking of immune tolerance against self EGER and induction of autoimmunity against receptor-positive tumors should be another useful approach for the treatment of EGFRpositive tumor cells with active immunization. We have previously shown human EGFR as a xenoantigen inducing specific immune responses in mouse and cross-reacting with mouse EGFR and it resulted in therapeutic benefits for EGFR-positive mouse tumors (9) . Our further studies showed that a recombinant form of extracellular domain of mouse EGFR, in the presence of DCs, could activate human peripheral T cells to proliferate. Therefore, the induced responses could cross-react with human EGFR and kill EGFR-positive human cancer cells (10) . However, whether the xenogeneic EGFR vaccine could induce humoral immunity responses against the EGFR-positive human tumors is not clear.
In this study, we firstly developed a methanol-trophic yeast expression system, Pichia pastoris (11) (12) (13) , which can express the secreted forms of murine EGFR ectodomain. Then the rabbits were subcutaneously vaccinated with the recombinant protein once a week for four weeks. The EGFR-positive human epidermoid carcinoma A431 was treated with the purified immune IgG in vitro and in vivo. Our data showed that the polyclonal IgG would efficiently inhibit the growth of tumor and increase the apoptotic rate of EGFR-positive human tumor cells. Interestingly, this therapy induced differentiation of the tumor cells in vivo.
Materials and methods
Preparation of recombinant EGFR. The nucleotide sequence encoding the extracellular domain of murine EGFR was PCR amplified from pcDNA3.1-mEGFR (9) and cloned into an expression vector pPICZ·A (Invitrogen). The recombinant plasmid was linearized by the restriction enzyme SacI and was transformed into P. pastoris GS115. The expression of the recombinant protein was performed, as previously described (11) (12) (13) . Briefly, a screened colony of yeast cells was selected and inoculated into 50 ml BMGY, shaken at 250 rpm for 1 day at 30˚C, the cells were pelleted and resuspended in 350 ml BMMY. Following further 2 days of induction at 30˚C, the recombinant mEGFR protein was secreted into the culture supernatant as a soluble form. The supernatant was harvested by centrifugation and analyzed by SDS-PAGE and Western blot analysis.
Purified mEGFR was prepared using a nickel-chelating column (Chelating Sepharose Fast Flow, Amersham Pharmacia Biotech, Uppsala, Sweden) on the chromatography system (AKTA, Amersham Pharmacia Biotech). The protein was eluted from the column with a linear gradient of imidazole, which was then dialyzed against the buffer containing decreased imidazole concentration (14) . Finally, it was dialyzed by phosphate-buffered saline (PBS). Purified proteins were confirmed by SDS-PAGE and Western blot analysis (9) .
Rabbit immunizations and isolation of immunoglobulin.
Purified mEGFR were dissolved in PBS before vaccinating and were mixed with an equal volume of aluminum hydroxide (ALUM) adjuvant at 1 mg/ml for 30 to 60 min as described (11) (12) (13) . The rabbits were subcutaneously immunized with mEGFR (0.5 mg per rabbit) once a week for four weeks in a volume of 0.2 ml, or appropriate control injections in a volume of 0.2 ml of PBS solution and ALUM adjuvant at the same time point. Serum from the rabbits, 2 weeks after the last treatment, was used for isolation of immune IgG. Preimmune IgG was prepared from rabbits prior to the first inoculation of mEGFR. Blood was allowed to clot overnight at 4˚C and serum was removed from the top of the mixture after centrifugation at 10,000 x g. Immunoglobulin was isolated using Econo-Pac serum IgG purification kit (Bio-Rad). Purified IgG (~20 mg/ml) (free of complement and other components) was obtained from 50 cc of rabbit blood per bleed as described (15) .
ELISA/Western blotting. For ELISA, tumor cells (5x10 3 ) were grown overnight in the wells of 96-well plates. The cells were fixed in 4% formalin for 5 min. Plates were washed with PBST (0.05% Tween-20 in PBS) and were blocked for 1 h at 37˚C with 200 μl/well blocking buffer (1% bovine serum albumin in PBST). The first antibody was diluted from 1:2000 to 1:20,000 in PBST was added for 2 h at 37˚C, followed by incubating with the second antibody (goat anti-rabbit conjugated to alkaline phosphatase, 1:10,000, Santa Cruz) for 30 min. Subsequently, alkaline phosphatase substrate BCIP/NCP (Sigma) was added to the wells. Enzyme activity was measured with an enzyme-linked immunosorbent assay (ELISA) reader (Bio-Rad Laboratories, Hercules, CA) (16) .
Western blot analysis was performed as described (16) . Briefly, purified mEGFR was separated by SDS-PAGE. Then gels were electroblotted with Sartoblot onto a polyvinylidene difluoride (PVDF) membrane. Membrane blots were blocked at 4˚C in 5% nonfat dry milk, washed and probed with rabbit sera at 1:3000. Blots were then washed and incubated with a alkaline phosphatase conjugated secondary antibody. The immunoreactive proteins were identified by using BCIP/NCP as the developing agent.
Cell line, media, growth conditions. Human epidermoid carcinoma A431 cells was obtained from the American Type Culture Collection (ATCC) and grew in DMEM supplement with 10% FBS. These tumor cell cultures were maintained in a 37˚C incubator with a humidified 5% CO 2 atmosphere.
Cell viability/MTT assays. The mEGFR antibody-mediated inhibition of tumor cell proliferation was carried out by MTT assays (15, 17) . Briefly, exponentially growing tumor cells (5x10 3 cells/well in 96-well plates) were incubated with varying concentrations of antibody (approximately no more than 1 mg/ml of protein) and then subjected to MTT assay. The antibody remained in the media for the full duration of the assay. Using daily time points, MTT reagent was added to the wells (5 mg/ml) and incubated at 37˚C for 4 h. Subsequently, the cells were solubilized with IPA/4N HCl. The samples were then read at wavelength of 570 nm.
Tumor growth inhibition study. All studies involving mice were approved by the Institute's Animal Care and Use Committee. Female athymic BALB/c nude mice, 6-8 weeks old, were maintained in pathogen-free conditions and fed sterile chow. A431 cells (1x10 6 ) in 0.1 ml of PBS were injected s.c. into the right flank of each mouse. The animals were randomly assigned into one of the following three groups (n=5) and treated with PBS, pre-immune IgG or immune IgG. Mice were i.v. treated with the purified IgG at 100 mg/kg 1 day before the mice were inoculated with the tumor cells and then twice per week for 4 weeks. Additional control animals were i.v. injected with same volume of PBS as described above. Tumor volume and survival time were observed. Tumor size was determined by caliper measurement of the largest and perpendicular diameters every 3 days. Tumor volume was calculated according to the formula V = 0.52ab 2 , where a is the largest superficial diameter and b is the smallest superficial diameter. The mice were sacrificed by cervical dislocation when they became moribund. Excised tumors were weighed before their fixation in 10% formalin (14, 16) .
Histological analysis. Sections of paraffin-embedded from each group were stained with hematoxylin and eosin (H&E), according to the standard procedures (14) . H&E section along the largest diameter of the tumor was scanned in the low field using the computer aided image analysis system Quantimet 600 and Qwin software (Leica, Benshaim, Germany). The total tumor area and necrotic tumor area were subsequently marked by the examiners on the screen. The percentage of the tumor necrosis area to total tumor area was evaluated by the image analysis system.
Quantitative assessment of apoptosis. Tumor sections were prepared, as described previously (14) . Terminal deoxynucleotidyl transferase-mediated nick end-labeling (TUNEL) staining was done using an in situ cell death detection kit (DeadEnd™ Fluorometric TUNEL System, Promega, Madison, USA) following the manufacturer's protocol. It is based on the enzymatic addition of digoxigenin-nucleotide to the nicked DNA by the recombinant terminal deoxynucleotidyl transferase (rTdT) (18) . In tissue sections, four equal-sized fields were randomly chosen and analyzed. Density was evaluated in each field, yielding the density of apoptotic cells (apoptosis index).
Statistical analysis. Data were assayed by ANOVA and Student's t-test. For the survival time of animals, Kaplan-Meier curves were established for each group and the survivals were compared by means of the log-rank test. Differences between means or ranks as appropriate were considered significant at P<0.05
Results
Expression and purification of mEGFR. Murine EGFR was expressed in P. pastoris GS115 secretively and SDS-PAGE analysis revealed that the recombinant protein with 6-His tag at the N-terminal was ~95 kDa (Fig. 1A) . Then, Nickel chelataffinity chromatography was employed to purify large quantities of mEGFR (14) and the recombinant protein was eluted from the column with 50 mmol imidazole. The presence of recombinant mEGFR in the eluted fractions was confirmed by SDS-PAGE (Fig. 1B) and Western blot analysis using an anti-mEGFR antibody (Fig. 1C) .
Characterizations of the polyclonal antibodies. To investigate the possibility that vaccination of rabbits with mEGFR could generate a cross-reacting response with human EGFR, the rabbits were inoculated with the purified recombinant mEGFR. Sera from mEGFR-immunized rabbits were assayed for the presence of mEGFR-specific autoantibodies in Western blot analysis. Only sera from rabbits immunized with mEGFR recognized the recombinant protein in Western blot analysis (Fig. 2) . In contrast, the sera isolated from the pre-immunized sera showed negative staining (Fig. 2) . Pre-immune and immune IgG were tested for their ability to bind EGFRpositive or -negative tumor cells of both mouse and human origins (Fig. 3) . There was a 4-9-and 3-8-fold difference in the binding of LL/2c and A431 (EGFR-positive) cells by immune antibody compared with pre-immune. The binding (Fig. 3A) . However, no significant difference was observed in the binding of EGFR-negative tumor cells by immune IgG compared with the pre-immune (Fig. 3B) . 
Rabbit immune IgG inhibits EGFR-positive tumor cell proliferation in vitro but not the EGFR-negative tumor cells.
The inhibition of tumor cell proliferation by rabbit immune IgG was determined by MTT assays. There was a dose response effect observed on the EGFR-positive murine (LL/2c) and human (A431) tumor cells for the immune IgG with 400 μg/ml and higher showing inhibition (Fig. 4A and B) . No effect was observed on the EGFR-negative (H22 and K562) tumor cells ( Fig. 4C and D) .
Tumor growth inhibition. Tumor volume and life span of mouse assay showed that the rabbit immune IgG resulted in effective suppression of tumor growth. Treatment with the immune IgG resulting in an 8 day delay of tumor growth to reach a volume of 800 mm 3 compared with PBS control (Fig. 5A) . Therapy with the immune IgG resulted in a significant increase in life span (P<0.01, by log-rank test; Fig. 5B ). Immune IgG treatment resulted in apparent tumor inhibition vs. PBS controls (P<0.01) or pre-immune IgG. Tumor growth inhibition was calculated using the mean excised tumor weight after completion of treatment for each group.
Histological analysis. Histologically, those immune IgGtreated tumors showed visible responses with homogeneous necrosis that was distinguishable in size and morphology from those of the control groups. Tumor tissues from the control mice had large areas of cancer nest, horny pearl and intercellular bridge, which are typical pathological signs associated with epithelial human squamous carcinoma (Fig. 6B and C) . Wherease, tumor tissues from mEGFR group had almost none of these typical pathological signs and considerable epithelial cyst spread in the tumor tissues (Fig. 6A) . subjected to terminal deoxynucleotidyl transferase-mediated nick end-labeling assays for the respective determination of apoptotic index. Immune IgG therapy resulted in a significant increase of apoptotic cancer cells (Fig. 7) . Data are shown as the mean apoptotic index ± standard deviations of cancer cells as percent normalized to apoptotic index of cancer cells (Fig. 7) .
Discussion
EGFR is a well-characterized tumor-associated antigen overexpressed in many human tumors, including non-small cell lung cancer (NSCLC) (19, 20) , cancer of the breast (21), the bladder (22) and the brain (23) and has served as a target for various antitumor therapies (1, (5) (6) (7) (8) (9) (10) 24) . The success of some anti-EGFR monoclonal antibodies, including C225 (also known as cetuximab), ABX-EGF and mAb 806 (6) (7) (8) , suggested that therapeutic cancer vaccines inducing anti-EGFR antibodies could also work (25) . However, the immunity to self EGFR is presumably difficult to elicit by vaccines based on self or syngeneic EGFR due to the immune tolerance acquired during the development of immune system (9) . Our group has previously reported immunization of mice with the plasmid DNA encoding human EGFR as vaccine by the breaking of the immune tolerance against EGFR in a cross-reaction between the xenogeneic homologous and self EGFR (9) . Our further studies were designed to investigate the possible of application of this strategy for the treatment of human tumors and found that the recombinant truncated mouse EGFR could induce human T lymphocyte responses against EGFRpositive human tumor cells (10).
The present study was designed to test whether the mEGFR vaccine could induce a humoral immunity against the EGFR-positive human tumor cells. Our results showed that the purified IgG from the rabbits immunized with recombinant mEGFR cross-reacted with the xenogeneic homologous EGFR (Fig. 3) and inhibit the proliferation of the EGFRpositive murine and human tumor cells (Fig. 4) . In vivo studies demonstrated that the IgG reduced the growth of tumor and improved the survival time of tumor-bearing mice (Fig. 5) .
The mechanism of the antineoplastic effect of the polyclonal IgG may be related to an inhibitory or apoptotic effect on the EGFR-positive tumor cells. We observed that the immune IgG inhibited the proliferation of EGFR-positive tumor cells in vitro, while the EGFR-negative ones did not. Though the antineoplastic activity seen in vivo appears to be broad, the antitumor efficacy of the immune IgG may in part result from the increased induction of apoptosis. This suggestion is supported by the present finding. More apparent apoptotic cells in the tumors treated with the immune IgG was found compared with the pre-immune or PBS groups (Fig. 7) . Previously, evidence indicated that EGFR blockade leads to the observed increase in tumor cell apoptosis (26) (27) (28) . Our findings, that the inducing of apoptosis within tumor cells is through the blocking of EGFR, coincide with previous studies (26) (27) (28) . by directing terminal differentiation (26, 29, 30) . These studies also provided evidence for a relationship between the in vivo antitumor activity of xenogeneic homologous induced IgG and their capacity to induce differentiation of cancer cells. EGFR is one of the multifunctional transmembrane proteins with intrinsic tyrosine kinase activity and post-translational modifications inducing structural changes are important to the functions of the protein (31) (32) (33) . Recently, Li et al suggested that the antibodies against the extracellular region of EGFR are structure based (34) . Thus, the properly modified and folded recombinant EGFR may be important to induce antibodies against the EGFR-positive tumor. In this study, we utilized the methylotrophic yeast Pichia pastoris (11) (12) (13) , one of the widely used eukaryotic organisms for expression of recombinant proteins, to express the mEGFR. The Pichia expression system is known to possess post-translational mechanisms which produce recombinant proteins with biological functions that are almost similar to the native proteins (35) . Our results showed that the IgG from the rabbits immunized with the recombinant mEGFR was successfully cross-reacted with the xenogeneic homologous EGFR and efficiently inhibited the growth of the A431 xenograft tumors.
In summary, the present study showed that the purified IgG from the rabbits immunized with recombinant mEGFR expressed in Pichia pastoris, which may increase the antigenicity and immunogenicity of the antigen, crossreacted with xenogeneic homologues and inhibit the growth of human EGFR-positive tumors in vitro and in vivo. The present findings provide further evidence of the anti-tumor effects of xenogeneic EGFR and may be of importance for the further exploration of the application of this vaccine in the protection and treatment of human cancer.
